Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Michael J. Iatropoulos, Daniel R. Cerven, George deGeorge, Eckhard von Keutz & Gary M. Williams. (2008) Reduction by Dietary Matrix Metalloproteinase Inhibitor BAY 12-9566N of Neoplastic Development Induced by Diethylnitrosamine, N-nitrosodimethylamine, or 7,12-dimethylbenz(a)anthracene in Rats. Drug and Chemical Toxicology 31:3, pages 305-316.
Read now
Read now
Articles from other publishers (20)
Li-Te Chin, Ke-Wei Liu, Yi-Han Chen, Shu-Ching Hsu & Lin Huang. (2021) Cell-based assays and molecular simulation reveal that the anti-cancer harmine is a specific matrix metalloproteinase-3 (MMP-3) inhibitor. Computational Biology and Chemistry 94, pages 107556.
Crossref
Crossref
Daniel E. Levy, Zhongli Ding, Chiwei Hu & Samuel Zalipsky. (2010) PEGylated iminodiacetic acid zinc complex stabilizes cationic RNA-bearing nanoparticles. Bioorganic & Medicinal Chemistry Letters 20:18, pages 5499-5501.
Crossref
Crossref
H. Hirte, I.B. Vergote, J.R. Jeffrey, R.N. Grimshaw, S. Coppieters, B. Schwartz, D. Tu, A. Sadura, M. Brundage & L. Seymour. (2006) A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study. Gynecologic Oncology 102:2, pages 300-308.
Crossref
Crossref
H. Hirte, D. Stewart, R. Goel, E. Chouinard, S. Huan, S. Stafford, B. Waterfield, S. Matthews, C. Lathia, B. Schwartz, V. Agarwal, R. Humphrey & and L. Seymour. (2005) An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Investigational New Drugs 23:5, pages 437-443.
Crossref
Crossref
Kenneth R. Hande, Mary Collier, Linda Paradiso, Jill Stuart-Smith, Mary Dixon, Neil Clendeninn, Geoff Yeun, Donna Alberti, Kim Binger & George Wilding. (2004) Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor. Clinical Cancer Research 10:3, pages 909-915.
Crossref
Crossref
W.R. Parulekar & E.A. Eisenhauer. (2002) Novel endpoints and design of early clinical trials. Annals of Oncology 13, pages 139-143.
Crossref
Crossref
Jane E. Weder, Carolyn T. Dillon, Trevor W. Hambley, Brendan J. Kennedy, Peter A. Lay, J.Ray Biffin, Hubert L. Regtop & Neal M. Davies. (2002) Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coordination Chemistry Reviews 232:1-2, pages 95-126.
Crossref
Crossref
C. Erlichman, A.A. Adjei, S.R. Alberts, J.A. Sloan, R.M. Goldberg, H.C. Pitot, J. Rubin, P.J. Atherton, G.G. Klee & R. Humphrey. (2001) Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Annals of Oncology 12:3, pages 389-395.
Crossref
Crossref
H. Hirte, R. Goel, P. Major, L. Seymour, S. Huan, D. Stewart, J. Yau, A. Arnold, S. Holohan, B. Waterfield, S. Bates, K. Bennett, W. Walsh & I. Elias. (2000) A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Annals of Oncology 11:12, pages 1579-1584.
Crossref
Crossref
Jerry W. Skiles, Lauren G. Monovich & Arco Y. Jeng. 2000.
167
176
.
Julie M. Cherrington, Laurie M. Strawn & Laura K. Shawver. 2000.
1
38
.
J. D. Becherer, M. H. Lambert & R. C. Andrews. 2000. Proteases as Targets for Therapy. Proteases as Targets for Therapy
235
258
.
José Marı́a Gutiérrez, Alexandra Rucavado & Michael Ovadia. (1999) Metalloproteinase inhibitors in snakebite envenomations. Drug Discovery Today 4:11, pages 532-533.
Crossref
Crossref
Kay M. SouthgateDheeraj MehtaMohammed B. IzzatAndrew C. NewbyGianni D. Angelini. (1999) Increased Secretion of Basement Membrane–Degrading Metalloproteinases in Pig Saphenous Vein Into Carotid Artery Interposition Grafts. Arteriosclerosis, Thrombosis, and Vascular Biology 19:7, pages 1640-1649.
Crossref
Crossref
D. R. SHALINSKY, J. BREKKEN, H. ZOU, C. D. MCDERMOTT, P. FORSYTH, D. EDWARDS, S. MARGOSIAK, S. BENDER, G. TRUITT, A. WOOD, N. M. VARKI & K. APPELT. (1999) Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials. Annals of the New York Academy of Sciences 878:1 INHIBITION OF, pages 236-270.
Crossref
Crossref
JERAULD S. SKOTNICKI, ARIE ZASK, FRANCES C. NELSON, J. DONALD ALBRIGHT & JEREMY I. LEVIN. (1999) Design and Synthetic Considerations of Matrix Metalloproteinase Inhibitors. Annals of the New York Academy of Sciences 878:1 INHIBITION OF, pages 61-72.
Crossref
Crossref
Anna Katrin Szardenings, Valery Antonenko, David A. Campbell, Nuria DeFrancisco, Satoru Ida, Lihong Shi, Nikolai Sharkov, David Tien, Yongwen Wang & Marc Navre. (1999) Identification of Highly Selective Inhibitors of Collagenase-1 from Combinatorial Libraries of Diketopiperazines. Journal of Medicinal Chemistry 42:8, pages 1348-1357.
Crossref
Crossref
Jerauld S. Skotnicki, Jeremy I. Levin, Arie Zask & Loran M. Killar. 1999. Metalloproteinases as Targets for Anti-Inflammatory Drugs. Metalloproteinases as Targets for Anti-Inflammatory Drugs
17
57
.
David R. Shalinsky, John Brekken, Helen Zou, Stan Kolis, Alexander Wood, Stephanie Webber & Krzysztof Appelt. (1998) Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Investigational New Drugs 16:4, pages 303-313.
Crossref
Crossref
Linda L Johnson, Richard Dyer & Donald J Hupe. (1998) Matrix metalloproteinases. Current Opinion in Chemical Biology 2:4, pages 466-471.
Crossref
Crossref